Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-CD48A in Relapsed or Refractory Multiple Myeloma
NCT03379584Phase 1Terminated
- Sponsor
- Seagen Inc.
- Start
- Feb 2018
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SGN-CD48A in multiple myeloma (MM), sponsored by Seagen Inc. Primary endpoints: Type, incidence, severity, seriousness, and relatedness of adverse events, Incidence of laboratory abnormalities and 1 more. Started Feb 2018; status: terminated.
02
Drugs
SGN-CD48A
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03379584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03379584.